DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Adzenys Xr-odt is a drug marketed by Neos Theraps and is included in one NDA. There are four patents protecting this drug.
This drug has two patent family members in two countries.
The generic ingredient in ADZENYS XR-ODT is amphetamine. There are fifty-five drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the amphetamine profile page.
There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
Summary for ADZENYS XR-ODT
|Suppliers / Packagers:||1|
|Bulk Api Vendors:||1|
|Formulation / Manufacturing:||see details|
|Drug Prices:||Drug price information for ADZENYS XR-ODT|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for ADZENYS XR-ODT|
|DailyMed Link:||ADZENYS XR-ODT at DailyMed|
Recent Clinical Trials for ADZENYS XR-ODT
Identify potential brand extensions & 505(b)(2) entrants
|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||Phase 2|
|Duke University||Phase 2|
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Neos Theraps||ADZENYS XR-ODT||amphetamine||TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL||204326-001||Jan 27, 2016||RX||Yes||No||Start Trial||Start Trial||Y||Start Trial|
|Neos Theraps||ADZENYS XR-ODT||amphetamine||TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL||204326-005||Jan 27, 2016||RX||Yes||No||Start Trial||Start Trial||Y||Start Trial|
|Neos Theraps||ADZENYS XR-ODT||amphetamine||TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL||204326-006||Jan 27, 2016||RX||Yes||Yes||Start Trial||Start Trial||Y||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|